Posted by Michael Wonder on 20 Jun 2024
Golidocitinib approved in China as first in class JAK1 only inhibitor for the treatment of relapsed or refractory peripheral T-cell lymphoma
19 June 2024 - Golidocitinib is a first-in-class Janus kinase 1 only inhibitor approved for the treatment of relapsed/refractory PTCL based on results from the multinational pivotal JACKPOT8B study.
Dizal today announced that the National Medical Products Administration of China has approved golidocitinib for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma whose disease has progressed on or were refractory to at least one prior systemic therapy.
